Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Colorectal neoplasms | D015179 | — | — | 1 | 3 | — | — | 1 | 4 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | 2 | — | — | — | 3 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 2 | — | — | — | 3 |
Adenocarcinoma | D000230 | — | — | 1 | 2 | — | — | — | 3 |
Leukemia | D007938 | — | C95 | 2 | 1 | — | — | — | 2 |
Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 1 | — | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | — | 1 |
Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | HP_0100526 | C34.90 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia acute | D015479 | — | C92.5 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | — | 1 |
Drug common name | ONVANSERTIB |
INN | onvansertib |
Description | Onvansertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase PLK1. In addition, it is known to target serine/threonine-protein kinase PLK2, serine/threonine-protein kinase PLK3, and receptor-type tyrosine-protein kinase FLT3. |
Classification | Small molecule |
Drug class | serine/threonine kinase inhibitors |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CN1CCN(c2ccc(OC(F)(F)F)c(Nc3ncc4c(n3)-c3c(c(C(N)=O)nn3CCO)CC4)c2)CC1 |
PDB | — |
CAS-ID | 1034616-18-6 |
RxCUI | — |
ChEMBL ID | CHEMBL1738758 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 67RM91WDHQ (ChemIDplus, GSRS) |